TrialDermatologic therapy2019
When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab.
Giovanni Damiani et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
19 papers cite it
this papercites it